Johnson & Johnson (JNJ) Announces the FDA Approval of TECVAYLI plus DARZALEX FASPRO

Johnson & Johnson (NYSE:JNJ) is one of the best stocks that will always grow.

Johnson & Johnson (NYSE:JNJ) announced on March 5 that the U.S. Food and Drug Administration (FDA) granted approval for TECVAYLI® plus DARZALEX

® for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.

Management reported that the approval offers a potential new standard of care as early as the second line, bringing a novel treatment approach for the 40% of patients with multiple myeloma who experience disease relapse. TECVAYLI® and DARZALEX

work synergistically to prime and activate the immune system for the eradication of myeloma cells that express the BCMA protein.

In a separate development, JPMorgan lifted the price target on Johnson & Johnson (NYSE:JNJ) to $250 from $225 on March 5, maintaining a Neutral rating on the shares and citing its raised Tremfya estimates for the target boost. It told investors in a research note that the recent ramp of Tremfya in inflammatory bowel disease has driven outperformance for the product.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech. The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.